Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.07, for a total value of $81,210.00. Following the transaction, the insider now directly owns 5,802 shares of the company’s stock, valued at $157,060.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Eugene A. Bauer also recently made the following trade(s):
- On Monday, December 18th, Eugene A. Bauer sold 3,000 shares of Dermira stock. The shares were sold at an average price of $27.34, for a total value of $82,020.00.
Shares of Dermira Inc (DERM) opened at $27.35 on Friday. Dermira Inc has a 52-week low of $21.35 and a 52-week high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68. The stock has a market capitalization of $1,110.00, a P/E ratio of -4.39 and a beta of 0.80.
A number of equities analysts recently commented on the company. Leerink Swann reissued an “outperform” rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $43.00 price target (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and set a $45.00 price target on shares of Dermira in a research note on Monday, November 6th. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Finally, Guggenheim restated a “buy” rating and set a $30.00 price objective on shares of Dermira in a research report on Thursday, December 14th. Three investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $41.00.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
What are top analysts saying about Dermira? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dermira and related companies.